[{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Phase III","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"10","companyTruncated":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pemafibrate","moa":"PPAR alpha","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Celecoxib","moa":"COX-2","graph1":"Neurology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kowa Pharmaceuticals America \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Not Applicable"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Roflumilast","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America","highestDevelopmentStatusID":"12","companyTruncated":"Kowa Pharmaceuticals America \/ Kowa Pharmaceuticals America"},{"orgOrder":0,"company":"Kowa Pharmaceuticals America","sponsor":"DKSH","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"Pemafibrate","moa":"PPAR-alpha","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Kowa Pharmaceuticals America","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Kowa Pharmaceuticals America \/ DKSH","highestDevelopmentStatusID":"15","companyTruncated":"Kowa Pharmaceuticals America \/ DKSH"}]

Find Clinical Drug Pipeline Developments & Deals by Kowa Pharmaceuticals America

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : DKSH will undertake the responsibility for providing comprehensive Market Expansion Services for triglycerides lowering drug, Parmodia (pemafibrate).

                          Product Name : Parmodia

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 24, 2025

                          Lead Product(s) : Pemafibrate

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : DKSH

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Through the collaboration, Kowa will leverage its primary care sales force to market and promote Zoryve (roflumilast) to primary care practitioners & pediatricians for all FDA-approved indications.

                          Product Name : Zoryve

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 29, 2024

                          Lead Product(s) : Roflumilast

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Arcutis Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The primary efficacy endpoint met and studied was summed pain intensity difference from 0 to 48 hours (SPID0-48). SEGLENTIS (celecoxib) had a significantly greater effect on SPID0-48 (least-squares mean: −139.1 than tramadol, celecoxib or placebo.

                          Product Name : Seglentis

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 19, 2022

                          Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : K-877 (pemafibrate), a highly potent and selective peroxisome proliferator activator receptor-alpha modulator for treatment of hyperlipidemia in Japan under brand name PARMODIA, will discontinue by DSMB who concluded that primary endpoint was unlikely to...

                          Product Name : K-877

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2022

                          Lead Product(s) : Pemafibrate

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the terms of the agreements, ESTEVE has granted KPA exclusive rights to commercialize E-58425 in the United States. E-58425 is a new product comprised of a co-crystal form of celecoxib and tramadol for the management of acute pain in adults.

                          Product Name : E-58425

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 03, 2021

                          Lead Product(s) : Celecoxib,Tramadol Hydrochloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase III

                          Recipient : Esteve Huayi Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank